NCT06229496View on ClinicalTrials.gov

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
COMBINATION_PRODUCT

Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)

Dose escalation study-dose level 1

COMBINATION_PRODUCT

Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)

Dose escalation study-dose level 2

COMBINATION_PRODUCT

Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)

Dose escalation study-dose level 3

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

Chang-Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City

RECRUITING

Chang-Gung Memorial Hospital, Linkou Branch, Taoyuan District

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER